AAV-DC

AAV-DC refers to a dendritic cell therapy in which dendritic cells are transduced or modified using an adeno-associated virus (AAV) vector. Adeno-associated viruses (AAVs) are small, non-enveloped viruses from the Parvoviridae family, widely used as vectors for gene therapy due to their low pathogenicity and ability to deliver genetic material into both dividing and non-dividing cells[1][3][5]. In the context of "AAV-DC," this typically means that dendritic cells have been engineered ex vivo with an AAV vector carrying a therapeutic gene or antigen, then administered as a cellular immunotherapy—often for cancer or infectious disease indications. The mechanism of action involves the presentation of encoded antigens by the modified dendritic cells to activate T-cell mediated immune responses against target diseases.